| Date | Title | Description |
| 23.04.2025 | Bridging the Gap in Seronegative Rheumatoid Arthritis: Unlocking the Diagnostic and Prognostic Potential of RA33 Autoantibodies, Upcoming Webinar Hosted by Xtalks | www.avisetest.com/provider
In this free webinar, gain insight into the critical diagnostic and prognostic challenges clinicians face when managing seronegative rheumatoid arthritis (SN RA) due to the absence of conventional serological biom... |
| 26.02.2025 | Rethinking Lupus: The Emerging Role of T Cells in SLE Pathophysiology and Diagnostics, Upcoming Webinar Hosted by Xtalks | www.avisetest.com/provider
Join this free webinar to explore how the understanding of systemic lupus erythematosus (SLE) has evolved from a disease primarily driven by B cells and Type I interferon to the growing recognition of T Cells' cru... |
| 21.11.2024 | Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by Xtalks | www.avisetest.com/provider
Join this free webinar to deepen your understanding of how emerging biomarkers for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) can provide diagnostic clarity in cases where ambiguous disease s... |
| 06.05.2024 | Exagen Announces Campaign for Lupus Awareness Month | CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patie... |
| 08.03.2024 | Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum | - |
| 07.03.2024 | Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 | - |
| 02.01.2024 | Health | A new test could save arthritis patients time, money and pain. But will it be used? | Arthur Allen | KFF Health News (TNS)
SAN DIEGO — Erinn Maury knew Remicade wasn’t the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte’s swollen, painful joints ... |
| 13.11.2023 | Exagen Inc. Reports Strong Third Quarter 2023 Results | SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. |
| 07.08.2023 | Exagen Inc. Reports Strong Second Quarter 2023 Results | SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. |
| 24.07.2023 | Exagen Inc. Appoints Paul Kim to Board of Directors | SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 202... |
| 15.05.2023 | Exagen Inc. Reports First Quarter 2023 Results | Record Physician Demand for AVISE® CTD |
| 20.03.2023 | Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results | Record AVISE® CTD Volume in 2022 |
| 27.09.2022 | ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health | NORTHBROOK, Ill., Sept. 27, 2022 (GLOBE NEWSWIRE) -- ADM Diagnostics, Inc. (ADMdx) has been awarded a two-year $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Aging (NIA) to develop a d... |
| 26.08.2022 | Octopus rolls out €220 million to drive green power generation, backs Exagen to build largest battery in UK | British renewable energy group specialising in sustainable energy, Octopus Energy Group has unveiled a €220 million fund to drive new green power generation to reduce Europe’s gas reliance. Dubbed the Octopus Energy Development Partnership ... |
| 04.08.2022 | Exagen Inc. Reports Second Quarter 2022 Results | Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters |
| 09.01.2022 | Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection | SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license... |
| 10.11.2021 | Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering | ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage,... |
| 10.11.2021 | Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering | ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage,... |
| 25.10.2021 | Exagen Inc :. Announces $27.2 Million Debt Refinancing | SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an aff... |
| 15.06.2021 | SQI DIAGNOSTICS INC.
SQI Diagnostics Inc. : Announces $3.9 Million Funding via Warrant Exercise by Insiders | TORONTO, June 15, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for ... |
| 15.06.2021 | SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders | |
| 16.11.2020 | Exagen and GSK Partner for Fourth Straight Year | Continued collaboration drives greater awareness of challenges facing lupus diagnosis and management |
| 12.10.2020 | New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors | Findings support the clinical need for an improved SLE diagnostic test |
| 29.09.2020 | Exagen Inc. Announces Agreement with Provider Network of America | Expanding Access for AVISE® Tests to 8 Million Members |
| 23.09.2020 | Exagen Appoints Wendy Johnson to Board of Directors | Additional independent board member will also serve on Audit Committee |
| 28.07.2020 | Exagen Inc. Reports Second Quarter 2020 Results | Testing experiencing monthly sequential improvement; record gross margins of 63% |
| 10.12.2019 | National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board | Members include Dr. Arthur Weinstein, Dr. Joel Kremer, Dr. Anca Askanase, Dr. Andrew Concoff, Dr. Maureen McMahon, and Dr. Vasileios Kyttaris |
| 22.11.2019 | Exagen Extends Agreement with GSK for a Third Year | Continued collaboration to drive greater awareness about challenges facing lupus diagnosis and management |
| 19.08.2019 | Exagen and the University of Washington Collaborate on Lupus and Rheumatoid Arthritis Research | Focus on the development of more effective tools to diagnose, prognose and monitor these diseases. |
| 30.07.2019 | Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson | Exagen reinforces board with extensive experience across the laboratory testing and healthcare sectors |
| 02.01.2019 | Exagen Enters Second-Year Agreement with GSK | Collaboration to drive greater awareness about challenges facing lupus diagnosis and management |
| 11.09.2017 | Exagen Diagnostics Receives Up To $25M in Debt Financing | Exagen Diagnostics Inc., a Vista, CA- and Albuquerque, NM-based commercial stage specialty diagnostic company, received up to $25m in debt financing.
An affiliate of Innovatus Capital Partners, LLC, provided the term loans.
The company inte... |
| 11.09.2012 |
Exagen Diagnostics Finds $5.3M
| Exagen Diagnostics, a venture-backed developer of molecular diagnostics testing which operates its main laboratory in Vista, California, said it has raised $5.3M. The funding was led by Tullis Health Invesotrs, and also included Sun Mountai... |
| 11.09.2012 | Exagen Diagnostics Raises $5.3M in Equity Funding | Exagen Diagnostics, a Vista, Calif.-based commercial-stage specialty diagnostic company, has raised $5.3m in equity funding.
The round was led by Tullis Health Investors, with participation from Sun Mountain Capital, Cottonwood Technology F... |
